Amoéba has received marketing authorization in France for its biofungicide AXPERA
Chassieu, July 01, 2026 (GLOBE NEWSWIRE) -- Amoéba (FR0011051598 - ALMIB), industrial greentech specialized in the development of natural microbiological solutions, announces that it has obtained marketing authorization for its biofungicide AXPERA in France. This first authorisation, granted by ANSES following the evaluation conducted by France in its capacity as rapporteur Member State for European Union, now allows the other concerned Member States concerned to proceed with and finalise thei
Chassieu, July 01, 2026 (GLOBE NEWSWIRE) -- Amoéba (FR0011051598 - ALMIB), industrial greentech specialized in the development of natural microbiological solutions, announces that it has obtained marketing authorization for its biofungicide AXPERA in France. This first authorisation, granted by ANSES following the evaluation conducted by France in its capacity as rapporteur Member State for European Union, now allows the other concerned Member States concerned to proceed with and finalise their national authorisation procedures in the coming weeks and months, according to each country’s specific timelines.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.